This company listing is no longer active
4D pharma Management
Management criteria checks 3/4
Key information
Duncan Peyton
Chief executive officer
US$343.5k
Total compensation
| CEO salary percentage | 98.8% |
| CEO tenure | 9yrs |
| CEO ownership | 5.6% |
| Management average tenure | 8.7yrs |
| Board average tenure | 4.1yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2021 | US$343k | US$339k | -US$32m |
| Sep 30 2021 | n/a | n/a | -US$36m |
| Jun 30 2021 | n/a | n/a | -US$41m |
| Mar 31 2021 | n/a | n/a | -US$36m |
| Dec 31 2020 | US$139k | US$137k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$30m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$135k | US$132k | -US$30m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$32m |
| Mar 31 2019 | n/a | n/a | -US$32m |
| Dec 31 2018 | US$130k | US$127k | -US$30m |
| Sep 30 2018 | n/a | n/a | -US$28m |
| Jun 30 2018 | n/a | n/a | -US$25m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$136k | US$136k | -US$28m |
| Sep 30 2017 | n/a | n/a | -US$25m |
| Jun 30 2017 | n/a | n/a | -US$22m |
| Mar 31 2017 | n/a | n/a | -US$17m |
| Dec 31 2016 | US$124k | US$124k | -US$12m |
Compensation vs Market: Duncan's total compensation ($USD343.49K) is about average for companies of similar size in the UK market ($USD341.99K).
Compensation vs Earnings: Duncan's compensation has increased whilst the company is unprofitable.
CEO
Duncan Peyton (52 yo)
9yrs
Tenure
US$343,489
Compensation
Mr. Duncan Joseph Peyton is a Co-founder of Retroscreen Virology Group plc. Mr. Peyton serves as Chief Executive Officer at 4D pharma plc. since February 2014.Mr. Peyton served at Aquarius Equity Partners...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 9yrs | US$343.49k | 5.55% $ 1.7m | |
| Chief Scientific Officer & Executive Director | 8.7yrs | US$294.81k | 5.4% $ 1.6m | |
| Chief Financial Officer | 1.1yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel (Interim) | no data | no data | no data | |
| Executive Vice President of Corporate Development | no data | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of CMC & Process Development | no data | no data | no data | |
| Executive Vice President of Research | no data | no data | no data |
8.7yrs
Average Tenure
50yo
Average Age
Experienced Management: DDDD's management team is seasoned and experienced (8.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 9.1yrs | US$343.49k | 5.55% $ 1.7m | |
| Chief Scientific Officer & Executive Director | 9.1yrs | US$294.81k | 5.4% $ 1.6m | |
| Independent Non-Executive Director | 1.9yrs | US$90.61k | no data | |
| Independent Non-Executive Director | 4.1yrs | US$93.31k | no data | |
| Independent Non-Executive Director | 2.4yrs | US$93.31k | no data | |
| Independent Non-Executive Director | 3.5yrs | US$100.07k | no data | |
| Independent Non-Executive Chairperson | 4.1yrs | US$139.29k | 0.017% $ 5.0k |
4.1yrs
Average Tenure
59yo
Average Age
Experienced Board: DDDD's board of directors are considered experienced (4.1 years average tenure).